New drug duo shows promise for rare blood cancer
NCT ID NCT04763616
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 2 study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with relapsed or refractory NK/T-cell lymphoma, a rare and aggressive blood cancer. The goal was to see if the combination could shrink tumors or stop the cancer from growing. Participants received the drugs for up to two years, and researchers measured how many achieved a complete response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
isatuximab and cemiplimab
What this could lead to
If successful, this combination could offer a new treatment option for people with hard-to-treat NK/T-cell lymphoma, potentially improving response rates.
What could go wrong
This is a small, early-phase study (37 participants) with no control group, so results may not be definitive. The drugs can cause significant side effects, and the cancer may still progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE NK CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- T-Cell Lymphoma Master Repository Study NCT05978141
- Predicting NK/T-Cell Lymphoma Treatment Response NCT07409168
- PD-1 Therapy & Radiotherapy for NK/T-cell Lympho NCT07380984
- Romidepsin in Stem Cell Transplant for T-Cell Ca NCT02512497
- Linperlisib Combo for Lymphoma Trial NCT07195799
- DR-01 for Leukemia & Lymphoma Trial (NCT05475925)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Samsung Medical Center
Seoul, Kangnamgu, 06351, South Korea